Differential In Vitro Effects of Intravenous versus Oral Formulations of Silibinin on the HCV Life Cycle and Inflammation
2011

Effects of Silibinin and Its Intravenous Formulation on Hepatitis C Virus

publication 10 minutes Evidence: moderate

Author Information

Author(s): Jessica Wagoner, Chihiro Morishima, Tyler N. Graf, Nicholas H. Oberlies, Elodie Teissier, Eve-Isabelle Pécheur, John E. Tavis, Stephen J. Polyak

Primary Institution: University of Washington

Hypothesis

Silibinin and its intravenous formulation SIL exhibit differential effects on the hepatitis C virus lifecycle and inflammation.

Conclusion

SIL shows stronger antiviral activity against HCV compared to silibinin, particularly in inhibiting viral replication and inflammation.

Supporting Evidence

  • SIL inhibited HCV RNA levels in vivo when administered intravenously.
  • Silibinin did not significantly inhibit HCV replication in certain cell lines.
  • Both formulations inhibited T cell proliferation to similar degrees.

Takeaway

This study shows that two forms of a plant extract can help fight a virus that causes liver disease, but they work in different ways.

Methodology

The study involved in vitro assays to compare the antiviral and anti-inflammatory effects of silibinin and its intravenous formulation SIL on HCV.

Limitations

The study primarily focuses on in vitro results, which may not fully translate to in vivo efficacy.

Participant Demographics

Healthy subjects provided blood samples for the study.

Digital Object Identifier (DOI)

10.1371/journal.pone.0016464

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication